United Therapeutics Co. (NASDAQ:UTHR – Get Rating) – Analysts at Wedbush decreased their FY2025 earnings per share (EPS) estimates for United Therapeutics in a research report issued on Tuesday, September 20th. Wedbush analyst A. Argyrides now anticipates that the biotechnology company will post earnings per share of $18.88 for the year, down from their prior estimate of $19.52. Wedbush currently has a “Outperform” rating and a $263.00 target price on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $14.90 per share. Wedbush also issued estimates for United Therapeutics’ FY2026 earnings at $30.18 EPS.
UTHR has been the subject of a number of other reports. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday. Bank of America reiterated an “underperform” rating on shares of United Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $250.14.
United Therapeutics Stock Performance
United Therapeutics (NASDAQ:UTHR – Get Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported $2.41 earnings per share for the quarter, missing the consensus estimate of $4.10 by ($1.69). United Therapeutics had a return on equity of 15.50% and a net margin of 35.27%. The firm had revenue of $466.90 million for the quarter, compared to the consensus estimate of $461.06 million. During the same quarter in the previous year, the business earned $3.65 EPS. The firm’s quarterly revenue was up 4.6% on a year-over-year basis.
Insider Buying and Selling
In other United Therapeutics news, Director Raymond Dwek sold 2,160 shares of United Therapeutics stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $241.29, for a total value of $521,186.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Christopher Causey sold 3,500 shares of the business’s stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $224.96, for a total transaction of $787,360.00. Following the sale, the director now owns 2,835 shares in the company, valued at approximately $637,761.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Dwek sold 2,160 shares of the stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $241.29, for a total value of $521,186.40. The disclosure for this sale can be found here. Insiders sold a total of 27,212 shares of company stock worth $6,330,244 in the last ninety days. 12.40% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. American Century Companies Inc. increased its holdings in United Therapeutics by 904.3% in the first quarter. American Century Companies Inc. now owns 69,496 shares of the biotechnology company’s stock valued at $12,468,000 after purchasing an additional 62,576 shares during the period. Sigma Planning Corp acquired a new position in shares of United Therapeutics in the 1st quarter worth approximately $224,000. Charles Schwab Investment Management Inc. boosted its stake in shares of United Therapeutics by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 378,643 shares of the biotechnology company’s stock valued at $81,818,000 after purchasing an additional 5,358 shares during the last quarter. First Manhattan Co. bought a new stake in shares of United Therapeutics in the 1st quarter valued at $14,998,000. Finally, Farallon Capital Management LLC increased its position in shares of United Therapeutics by 18.4% during the first quarter. Farallon Capital Management LLC now owns 379,696 shares of the biotechnology company’s stock worth $68,121,000 after buying an additional 58,936 shares during the period. Institutional investors and hedge funds own 95.57% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.